Lucid Diagnostics (LUCD) said Thursday it closed an underwritten public offering of around 28.8 million common shares, including about 3.8 million shares issued under the full exercise of the overallotment option.
The company said it expects total net proceeds to be around $26.9 million, which its intends to use for working capital and general corporate purposes.
Price: 1.03, Change: +0.01, Percent Change: +0.98
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments